Clinical Trial Update: Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacology data for SNX-5422 mesylate in subjects with refractory solid tumor malignancies have been reported and the study is completed. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• SNX-5422 Mesylate (SNX-5422 mesylate)

Snippet

Sponsor: Esanex Inc. | Conditions: Cancer | Phase 1 | Status: COMPLETED